HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy.

Abstract
In epidemiologic studies, human immunodeficiency virus (HIV)-infected men on antiretroviral therapy (ART) are at higher risk of incident diabetes mellitus compared with women with similar treatment histories. We used metabolomics to determine whether a sex difference in plasma amino acids, acylcarnitines, and organic acids predictive of diabetes and impaired energy metabolism is present in HIV-infected persons on long-term ART.We enrolled 70 HIV-infected adults (43% women) on efavirenz, tenofovir, and emtricitabine (Atripla) with HIV-1 RNA <50 copies/mL for over 2 years. Half of the HIV-infected subjects were obese, and these were matched with 30 obese HIV-negative controls. All subjects had no history of diabetes, statin use, or heavy alcohol use. Fasting insulin sensitivity was measured using homeostatic model assessment 2 (HOMA2), and adipose tissue was measured using dual-energy x-ray absorptiometry (DEXA). Liquid chromatography/mass spectrometry was used to quantitate fasting plasma branched chain and aromatic amino acids predictive of incident diabetes, and C3 and C5 acylcarnitinines and organic acids indicative of impaired energy metabolism.HIV-infected women had more baseline risk factors for insulin resistance: women were older (46 vs 44 years) and had a longer ART duration (8.4 vs 5.1 years, P < 0.05 for both) compared with men but had similar CD4+ count (median 701 cells/μL), smoking and hepatic C prevalence, and body mass index (BMI) (median 30.3 kg/m). However, women had higher insulin sensitivity compared with men (P < 0.01), and lower plasma levels of isoleucine, leucine, valine, phenylalanine, and tyrosine (P < 0.01 for all), and lower C3 and C5 acylcarnitines (P < 0.01 for all), in multivariable regression models after adjusting for DEXA fat mass index, age, race, CD4+ count, smoking, and ART duration. In the obese HIV-infected subjects and HIV-negative controls, the relationship of sex and plasma metabolite levels did not significantly differ according to HIV-status.HIV-infected women on non-nucleoside reverse transcriptase inhibitor-based ART had superior glucose tolerance and lower plasma metabolites associated with the development of diabetes compared with men with similar metabolic disease risk profiles. The relationship between sex and plasma metabolite levels did not significantly differ according to HIV-status among obese subjects, suggesting the observed sex-differences may not be specific to HIV infection.
AuthorsJohn R Koethe, Cathy A Jenkins, Christopher Petucci, Jeffrey Culver, Bryan E Shepherd, Timothy R Sterling
JournalMedicine (Medicine (Baltimore)) Vol. 95 Issue 19 Pg. e3634 (May 2016) ISSN: 1536-5964 [Electronic] United States
PMID27175676 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Amino Acids, Branched-Chain
  • Anti-Retroviral Agents
  • Blood Glucose
  • Reverse Transcriptase Inhibitors
  • acylcarnitine
  • Carnitine
Topics
  • Absorptiometry, Photon
  • Adipose Tissue (metabolism)
  • Adiposity
  • Adult
  • Amino Acids, Branched-Chain (blood)
  • Anti-Retroviral Agents (administration & dosage, therapeutic use)
  • Blood Glucose (metabolism)
  • CD4 Lymphocyte Count
  • Carnitine (analogs & derivatives, blood)
  • Case-Control Studies
  • Diabetes Mellitus (metabolism, virology)
  • Fasting (blood)
  • Female
  • HIV Infections (complications, drug therapy, metabolism)
  • HIV Seronegativity
  • Humans
  • Insulin Resistance
  • Male
  • Metabolome
  • Middle Aged
  • Obesity (complications)
  • Regression Analysis
  • Reverse Transcriptase Inhibitors (therapeutic use)
  • Risk Factors
  • Sex Factors
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: